Variables associated with the risk of colorectal adenomas in asymptomatic patients with a family history of colorectal cancer.

Gaglia, P; Atkin, Wendy; Whitelaw, S. C.; Talbot, Ian C.; Williams, C. B.; Northover, J. M. A.; Hodgson, Shirley

doi:10.1136/gut.36.3.385

Cited by 58 publications

(20 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is important to bear in mind when examining these patient groups and to have an expectancy of frequent adenoma finding. These results support the assumption that a family history of CRC increases the risk for adenomas also where LS is not diagnosed [26][27][28][29][30]. In the OCR group, the difference was not statistically significant, although a tendency could be seen.…”

Section: Cancers and Adenomassupporting

confidence: 82%

Colonoscopy findings in high-risk individuals compared to an average-risk control population

Forsberg

Kjellström

Andréasson

et al. 2015

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Section: Cancers and Adenomassupporting

confidence: 82%

Colonoscopy findings in high-risk individuals compared to an average-risk control population

Forsberg

Kjellström

Andréasson

et al. 2015

Scandinavian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

“…In most other studies of first degree relatives of patients with CRC, the yield of adenoma has been lower, varying between 12 and 22% [13, 14, 15], but a figure of 39% was reported by Sauar et al [16]. …”

Section: Discussionmentioning

confidence: 99%

Screening of First Degree Relatives of Patients Operated for Colorectal Cancer: Evaluation of Fecal Calprotectin vs. Hemoccult II

Kristinsson¹,

Nygaard²,

Aadland

et al. 2001

Digestion

View full text Add to dashboard Cite

Fecal calprotectin (CPT) is elevated in the majority of patients with known colorectal cancer (CRC), but the specificity is not clarified. Aim: To evaluate if a CPT test (PhiCal ELISA) was more sensitive than Hemoccult II test in detecting colorectal neoplasia, and to obtain reference values in subjects with normal colonoscopy. To evaluate a possible relation between number and extent of dysplasia of adenomas in first degree relatives of patients with CRC and the stage of the carcinoma in the index casus. Further to study the prevalence of CRC and adenomas in the first degree relatives of patients operated for CRC. Method: In a multicenter study, 253 first degree relatives of patients with CRC, aged 50–75 years (mean age 60 years) underwent colonoscopy after having delivered stool samples and three Hemoccult II slides. Results: In 237 first degree relatives from 148 patients with CRC, polyps were found in 118 (50%). Seventy three (31%) had adenomas and 17 had adenomas ≧10 mm. Five had asymptomatic cancers. The specificity of fecal CPT for adenomas at cut off levels ≤10, ≤15 and ≤20 mg/l were 47.4, 59.6 and 71.1%, respectively (max of three samples). The sensitivity at same cut off levels was 56.2, 45.2 and 31.5% and 4/5 of patients with carcinoma had CPT values >15 mg/l. The sensitivity of Hemoccult II for adenomas was 8%, and 4/5 of patients with carcinoma had negative Hemoccult II. The specificity for adenomas was 95%. Conclusion: Fecal CPT test was more sensitive than Hemoccult II in detecting colorectal neoplasia but the specificity was lower. In a high risk group like first degree relatives of patients with CRC, there are good reasons to consider fecal CPT as a first test in selecting patients for endoscopy.

show abstract

“…This finding even extends to colonic adenomas (2). The sex-specific difference in colon cancer and precancerous lesion has been attributed to estrogen, whereas large-scale population studies found that postmenopausal estrogen use significantly reduces the risk of colon cancer (3,4).…”

Section: Introductionmentioning

confidence: 96%

Estrogen Stimulates the Expression of Mismatch Repair Gene hMLH1 in Colonic Epithelial Cells

Jin

Sheng

et al. 2010

Cancer Prevention Research

View full text Add to dashboard Cite

Estrogen is reported to have a protective effect on colon cancer; however, the underlying mechanism is unclear. Impaired mismatch repair plays an important role in colonic carcinogenesis. The purpose of this study was to investigate the association of estrogen on regulating mismatch repair expression in colonic epithelial cells. In cultured COLO205 cells, the effect of estradiol (E2) and antagonist ICI182.780 on the expression of hMLH1 and hMSH2 was studied using reverse transcription-PCR and Western blotting. The correlation between serum level E2 and the expression of hMLH1 and hMSH2 in colonic mucosal tissue of 42 healthy individuals was also examined using reverse transcription-PCR and immunohistochemical staining. E2 increased the expression of hMLH1 in COLO205 cells, which was suppressed by ICI182.780. However, the effect of E2 on hMSH2 expression was not significant in COLO205 cells. In healthy individuals, a strong positive correlation of E2 level with hMLH1 expression in normal colonic epithelial cell was observed when serum E2 level was >45 pg/mL, but no correlation was seen between E2 and hMSH2 expression. E2 affects the expression of hMLH1 but not hMSH2 in vitro, and high serum E2 level correlates with hMLH1 expression in vivo. These findings suggest that the anticolonic cancer effect of estrogen may be related to hMLH1 regulation.

show abstract

Variables associated with the risk of colorectal adenomas in asymptomatic patients with a family history of colorectal cancer.

Abstract: (Gut 1995; 36: 385-390)

Cited by 58 publications

References 20 publications

Colonoscopy findings in high-risk individuals compared to an average-risk control population

Colonoscopy findings in high-risk individuals compared to an average-risk control population

Screening of First Degree Relatives of Patients Operated for Colorectal Cancer: Evaluation of Fecal Calprotectin vs. Hemoccult II

Estrogen Stimulates the Expression of Mismatch Repair Gene hMLH1 in Colonic Epithelial Cells

Contact Info

Product

Resources

About